User Rating 0.0
Total Usage 1 times
Disclaimer: Statistical estimate only. Not a diagnosis.
U/mL
pmol/L
Is this tool helpful?

Your feedback helps us improve.

About

The Risk of Ovarian Malignancy Algorithm (ROMA) combines two serum biomarkers, HE4 and CA125, with menopausal status to stratify patients with an adnexal mass into high or low risk groups for epithelial ovarian cancer. HE4 is often more sensitive than CA125 for early-stage disease and less prone to elevation in benign gynecological conditions like endometriosis.

This tool applies the specific logistic regression coefficients derived from the Moore et al. multicenter trials. Accuracy depends heavily on the correct selection of the patient's menopausal status, as hormonal environments significantly alter biomarker baselines.

oncology ovarian cancer biomarkers CA125 HE4 ROMA score

Formulas

The algorithm calculates a Predictive Index (PI) which is then converted to a probability percentage.

Predictive Index (Pre-menopausal):

PI = 12.0 + 2.38 × ln(HE4) + 0.0626 × ln(CA125)

Predictive Index (Post-menopausal):

PI = 8.09 + 1.04 × ln(HE4) + 0.732 × ln(CA125)

ROMA Probability (%):

exp(PI)1 + exp(PI) × 100

Reference Data

Patient GroupROMA Score CutoffRisk Stratification
Pre-menopausal 11.4%High Risk of Malignancy
Pre-menopausal< 11.4%Low Risk
Post-menopausal 29.9%High Risk of Malignancy
Post-menopausal< 29.9%Low Risk

Frequently Asked Questions

Generally, it is defined as the absence of menstruation for at least 12 months or age >50 years if history is unreliable. However, the specific FDA-cleared ROMA protocols utilize local laboratory guidelines.
Ovarian cancer incidence increases with age, and benign conditions that elevate CA125 (like endometriosis) are more common in pre-menopausal women. The algorithm adjusts coefficients to maintain specificity across these distinct hormonal landscapes.
No. The ROMA index is a risk stratification tool, not a diagnostic test. A 'High Risk' result indicates the need for referral to a gynecologic oncologist for further evaluation, not a confirmation of malignancy.